Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Stock Short Interest Report for October

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 30,190 shares, an increase of 440.0% from the September 30th total of 5,591 shares. Based on an average trading volume of 39,784 shares, the short-interest ratio is presently 0.8 days. Approximately 0.7% of the shares of the company are short sold.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ:BGMS traded down $0.02 on Wednesday, hitting $0.92. The company’s stock had a trading volume of 4,271 shares, compared to its average volume of 761,189. The company has a market capitalization of $5.08 million, a price-to-earnings ratio of -0.25 and a beta of -0.39. Cyclacel Pharmaceuticals has a 12 month low of $0.57 and a 12 month high of $2.80. The stock’s 50-day moving average is $0.90 and its two-hundred day moving average is $0.98.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $0.34 million for the quarter. Cyclacel Pharmaceuticals had a negative net margin of 118.27% and a negative return on equity of 31.60%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Tuesday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. Its research programs are designed to target key proteins involved in tumor-cell growth, division and survival, with the goal of addressing cancers that have limited treatment options.

The company’s pipeline has included fadraciclib (CYC065), an investigational selective cyclin-dependent kinase 2 inhibitor, and sapacitabine (CYC682), an oral nucleoside analog studied in several oncology indications.